Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1.

Ashkenazi A, Viard M, Unger L, Blumenthal R, Shai Y.

FASEB J. 2012 Nov;26(11):4628-36. doi: 10.1096/fj.12-215111.

2.

Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.

Wang C, Shi W, Cai L, Lu L, Yu F, Wang Q, Jiang X, Xu X, Wang K, Xu L, Jiang S, Liu K.

J Antimicrob Chemother. 2014 Jun;69(6):1537-45. doi: 10.1093/jac/dku010.

PMID:
24500189
3.
4.

A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.

Murray EJ, Leaman DP, Pawa N, Perkins H, Pickford C, Perros M, Zwick MB, Butler SL.

J Virol. 2010 Jul;84(14):7288-99. doi: 10.1128/JVI.00535-10.

5.

Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.

He Y, Cheng J, Lu H, Li J, Hu J, Qi Z, Liu Z, Jiang S, Dai Q.

Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16332-7. doi: 10.1073/pnas.0807335105.

6.
7.

The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.

Chong H, Yao X, Qiu Z, Sun J, Qiao Y, Zhang M, Wang M, Cui S, He Y.

J Antimicrob Chemother. 2014 Oct;69(10):2759-69. doi: 10.1093/jac/dku183.

PMID:
24908047
8.

Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.

Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, Salgo M, Cammack N, Matthews T, Greenberg ML.

J Virol. 2005 Oct;79(19):12447-54.

9.

Resistance to enfuvirtide, the first HIV fusion inhibitor.

Greenberg ML, Cammack N.

J Antimicrob Chemother. 2004 Aug;54(2):333-40. Review.

PMID:
15231762
10.

Are fusion inhibitors active against all HIV variants?

Poveda E, Rodes B, Toro C, Soriano V.

AIDS Res Hum Retroviruses. 2004 Mar;20(3):347-8.

PMID:
15117459
11.

Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.

Chong H, Yao X, Qiu Z, Sun J, Zhang M, Waltersperger S, Wang M, Liu SL, Cui S, He Y.

FASEB J. 2013 Mar;27(3):1203-13. doi: 10.1096/fj.12-222547.

PMID:
23233535
12.

Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.

Su Y, Chong H, Qiu Z, Xiong S, He Y.

J Virol. 2015 Jun;89(11):5801-11. doi: 10.1128/JVI.00373-15.

13.

Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics.

Wang C, Lu L, Na H, Li X, Wang Q, Jiang X, Xu X, Yu F, Zhang T, Li J, Zhang Z, Zheng B, Liang G, Cai L, Jiang S, Liu K.

J Med Chem. 2014 Sep 11;57(17):7342-54. doi: 10.1021/jm500763m.

PMID:
25156906
14.

HIV entry inhibitors: mechanisms of action and resistance pathways.

Briz V, Poveda E, Soriano V.

J Antimicrob Chemother. 2006 Apr;57(4):619-27. Review.

PMID:
16464888
15.

Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.

Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardière JL, Pacanowski J, Meynard JL, Hance AJ, Clavel F, Mammano F.

J Virol. 2006 Sep;80(17):8807-19.

16.
17.

Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action.

Wexler-Cohen Y, Shai Y.

PLoS Pathog. 2009 Jul;5(7):e1000509. doi: 10.1371/journal.ppat.1000509.

18.

Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins.

Steffen I, Pöhlmann S.

Curr Pharm Des. 2010;16(9):1143-58.

PMID:
20030613
19.

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW.

Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54.

Supplemental Content

Support Center